The Market Reports

Synopsis
The global market for Eosinophilic Asthma Treatment was estimated to be worth US$ 35467 million in 2024 and is forecast to a readjusted size of US$ 306649 million by 2031 with a CAGR of 35.7% during the forecast period 2025-2031.
Eosinophilic asthma treatment focuses on managing a severe subtype of asthma characterized by elevated levels of eosinophils, a type of white blood cell that contributes to inflammation in the airways. Traditional therapies, such as inhaled corticosteroids and bronchodilators, often prove insufficient for patients with this phenotype. Monoclonal antibodies such as mepolizumab, reslizumab, and benralizumab target interleukin-5 (IL-5) or its receptor, effectively reducing eosinophil levels and decreasing the frequency of exacerbations. The management strategy also includes identifying eosinophilic biomarkers through blood tests or sputum analysis to ensure accurate diagnosis and therapy alignment.
Global key Eosinophilic Asthma treatment brands include Regeneron Pharmaceuticals & Sanofi, Genentech (Roche Group) & Novartis and GSK etc. The top 3 companies hold a share about 90%.
North America is the largset market with a share over 40%, followed by Europe and Asia-Pacific, with around 35% and 15% market share respectively.
In terms of treatment, subcutaneous injection is the largest segment with a share of 95%. And in terms of end users, adult is the largest end user with a share over 55%, followed by Teenagers, Children.
With a growing understanding of asthma phenotypes, more clinicians are identifying eosinophilic asthma as a distinct, inflammation-driven subtype, prompting targeted treatment approaches. Key biologic drugs such as mepolizumab, benralizumab, reslizumab, dupilumab, and the newer tezepelumab are gaining widespread usage due to their proven effectiveness in reducing exacerbation rates, improving lung function, and minimizing the need for oral corticosteroids.
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Asthma Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Eosinophilic Asthma Treatment by region & country, by Type, and by Application.
The Eosinophilic Asthma Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Asthma Treatment.
Market Segmentation
By Company
AstraZeneca
GSK
Genentech (Roche Group) & Novartis
Regeneron Pharmaceuticals & Sanofi
Teva Pharmaceuticals
Segment by Type
Intravenous Infusion
Subcutaneous Injection
Segment by Application
Children
Adults
Teenagers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Eosinophilic Asthma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Eosinophilic Asthma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Eosinophilic Asthma Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index